Hematology Oncology Research

Publications

Researchers within the UCLA Division of Hematology-Oncology routinely disseminate the findings of their impactful work through publications in top-tier journals. Keep up with their latest articles here.

September 2026

  1. Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S, Furuya H, Osipov A, Lorber J, Billet S, Morris A, Ten Hoeve-Scott J, Graeber T, Pandol SJ, Hendifar A, Bhowmick NA. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nat Cancer. 2026 Aug 31. doi: 10.1038/s43018-026-01225-z. Epub ahead of print. PMID: 42675216.
  2. Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison S, Lipsyc-Sharf M, Reduzzi C, Ademuyiwa FO, Puglisi F, Gradishar WJ, Ma CX, Bardia A, Cristofanilli M, Davis AA. Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival. Breast Cancer Res Treat. 2026 Sep 1;219(2):5. doi: 10.1007/s10549-026-08068-3. PMID: 42678609.
  3. Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar S, Bao L, Tao L, Vora R, Hegde A, Saltos A, Azad NS, Hong DS; RMC-6236-001 Investigators. Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Sep 3;395(9):882-893. doi: 10.1056/NEJMoa2504059. PMID: 42685317.
  4. Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs). J Cancer Surviv. 2026 Sep 4. doi: 10.1007/s11764-026-02109-y. Epub ahead of print. PMID: 42697984.
  5. Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark LN, Golmakani M, Jackson-Fisher A, Tang SY, Guo CC, Keliher EJ, Maresca K, Segal NH. A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers. Cancer Res Commun. 2026 Sep 4. doi: 10.1158/2767-9764.CRC-26-0101. Epub ahead of print. PMID: 42696650.
  6. Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West RM, Pillai P, Marinello P, Herrera AF. Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study. Blood Neoplasia. 2026 May 26;3(4):100252. doi: 10.1016/j.bneo.2026.100252. PMID: 42699247; PMCID: PMC13542932.
  7. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC, Garbaos G, Liberman M, Mirón MLL, Smyth EC, Cheng LY, Robbins SH, Valeri N, Xynos I, Tabernero J; MATTERHORN investigators. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet. 2026 Sep 9:S0140-6736(26)01254-7. doi: 10.1016/S0140-6736(26)01254-7. Epub ahead of print. PMID: 42716074.
  8. Levi A, Nasr A, Cui Y, Abbas AA, Arouchian TT, Coveler AL, Pierce TL, Anderson BT, Collisson E, Davelaar J, Lo SK, Gaddam S, Gong J, Osipov A, Hendifar AE. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Psychooncology. 2026 Sep;35(9):e70601. doi: 10.1002/pon.70601. PMID: 42714969.
  9. Muss HB, Sun C, Ding YC, Ji J, White TA, Nyrop K, LeBrasseur NK, Neuhausen SL, Mitin N, Sedrak MS. p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer. Geroscience. 2026 Sep 10. doi: 10.1007/s11357-026-02521-3. Epub ahead of print. PMID: 42720847.
  10. Wang S, Zhang Q, Jiang Z, Tong Z, Li W, Wang J, Ouyang Q, Yao T, Wang Y, Sun M, Wang X, Wang S, Zang A, Zhang Z, Chen W, Wang X, Li H, Sheng Y, Zhang B, Liu C, Zhao K, Munegowda MA, Bardia A, Xu B. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort. ESMO Open. 2026 Sep 11;11(10):108538. doi: 10.1016/j.esmoop.2026.108538. Epub ahead of print. PMID: 42727418.
  11. Li D, Garon EB. Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer. Clin Cancer Res. 2026 Sep 11. doi: 10.1158/1078-0432.CCR-26-2458. Epub ahead of print. PMID: 42726138.
  12. Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH. Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urol Oncol. 2026 Sep 12:S1078-1439(26)00703-9. doi: 10.1016/j.urolonc.2026.07.035. Epub ahead of print. PMID: 42731937.
  13. Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197. doi: 10.14740/jh2218. PMID: 42730167; PMCID: PMC13568759.
  14. Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov K, Wu MF, Akewanlop C, Vu HV, Lee KH, Huang X, Armenteros-Monterroso E, Rukazenkov Y, Herbst RS. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]. J Thorac Oncol. 2026 Sep 13:104179. doi: 10.1016/j.jtho.2026.104179. Epub ahead of print. PMID: 42732874.
  15. Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin Y, Ko M, Sayar E, Patton RD, Kollath L, Meis A, Lindergren S, Ji N, Ali K, Venkatesh H, Wladyka CL, McDeed AP, Mills CB, Vashisth M, Kim JY, Nadal R, Hawley JE, Yezefski TA, Psutka SP, Gore JL, Lin DW, Nelson PS, Cheng HH, Schweizer MT, Fong L, Lee JK, Yu EY, Corey E, Morrissey C, Grivas P, Montgomery RB, Wright JL, Haffner MC, Vakar-Lopez F, Mian OY, Lam HM, Hsieh AC, Ha G. Evolution and heterogeneity of lethal metastatic bladder cancer subtypes. Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11035-z. Epub ahead of print. PMID: 42749807.
  16. Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024. Cancer Med. 2026 Sep;15(9):e72223. doi: 10.1002/cam4.72223. PMID: 42745440.
  17. Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun T, Dugan J, Feld J, Gourin MP, Pigneux A, Robin JB, Schiller G, Stein E, Roth D, Kelly M, Pollyea D, de Botton S. Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study. Blood Neoplasia. 2026 Jul 28;3(4):100279. doi: 10.1016/j.bneo.2026.100279. PMID: 42761251; PMCID: PMC13586685.
  18. Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort. Microbiol Spectr. 2026 Sep 21:e0078326. doi: 10.1128/spectrum.00783-26. Epub ahead of print. PMID: 42765732.
  19. Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata D, Toriola AT, Ose J, Peoples AR, Hardikar S, Siegel EM, Bower JE, Gigic B, Hoogland AI, Li X, Small BJ, Kaufman H, Jim HSL, Figueiredo JC. Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer. J Natl Compr Canc Netw. 2026 Sep 22:1-8. doi: 10.6004/jnccn.2026.7035. Epub ahead of print. PMID: 42772330.
  20. Shitara K, Wainberg Z, Tabernero J, Van Cutsem E, Coutzac C, De La Fouchardière C, Lee J, Rha SY, Kang YK, Fanning P, Forgie A, Mao C, Brickman D, Pons J, Tsiatis AC, Randolph S, Lee KW. Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial. Nat Med. 2026 Sep 24. doi: 10.1038/s41591-026-04700-3. Epub ahead of print. PMID: 42786305.
  21. Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026 Sep 24:gutjnl-2026-339505. doi: 10.1136/gutjnl-2026-339505. Epub ahead of print. PMID: 42785981.
  22. Anand SK, Das S, Arias F, Richard KS, Rohilla S, Ghrayeb A, McKinney MP, Wang L, Tan L, Ding J, Kumar D, Pandey N, Lee J, Zhao Y, Mohajan S, Male G, Nunez K, Finney AC, Pearson-Gallion BH, Gade R, Maxie J, Liu Y, Kaur H, Pandit R, Ben Dhaou C, Eniafe J, Zhang X, Liu Z, Yurochko AD, Garcia-Barrio MT, Razani B, Chang F, Schopfer FJ, Huang X, Cai B, Gottlieb E, Wen B, Sun D, Liu W, Thevenot PT, Cohen AJ, Zhang J, Chen YE, Orr AW, Dhanesha N, Yurdagul A Jr, Rom O. Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. J Clin Invest. 2026 Sep 24:e204511. doi: 10.1172/JCI204511. Epub ahead of print. PMID: 42784330.
  23. Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge. Cureus. 2026 Aug 24;18(8):e115080. doi: 10.7759/cureus.115080. PMID: 42780982; PMCID: PMC13599747.
  24. Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a case study. Front Oncol. 2026 Sep 10;15:1681073. doi: 10.3389/fonc.2025.1681073. PMID: 42787686; PMCID: PMC13601985.
  25. Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig MB. Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease. CA Cancer J Clin. 2026 Sep-Oct;76(5):e70111. doi: 10.3322/caac.70111. PMID: 42806490; PMCID: PMC13620192.
View the full list of Hematology Oncology publications